オプションチェーンは、Autolus Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Autolus Therapeuticsの市場センチメントを評価します。.

Autolus Therapeutics (NASDAQ:AUTL) 株価情報, オプションチェーン

AUTOLUS THERAPEUTICS PLC

Autolus Therapeutics

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics PLC

Austal Ltd

News

Financing

ASNS

Actelis Networks Announces Private Placement Priced At-the-Market Under Nasdaq Rules; Aggregate Gross Proceeds ~$1M

Tesla&#8217;s Chinese competitor NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) recorded a modest uptick in premarket trading on Wednesday as the electric vehicle maker unveiled its delivery figures for June<a href="https://www.benzinga.com/pressreleases/25/07/g46189280/nio-inc-provides-june-and-second-quarter-2025-delivery-update" target="_blank" rel="noreferrer noopener"> and the second quarter of 2025</a>.
NIO shipped 24,925 units in June, reflecting a 17.5% increase over the same month last year.
The update comes amid renewed political debate over electric vehicles, as former President Donald Trump took aim at Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk in a social media post.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/politics/25/06/45943245/trump-says-he-was-amazed-that-tesla-ceo-elon-musk-endorsed-him-despite-his-anti-ev-stance" rel="noreferrer noopener">Trump Says He Was &#8216;Amazed&#8217; That Tesla CEO Elon Musk Endorsed Him Despite His Anti-EV Stance</a>
Trump <a target="_blank" href="https://truthsocial.com/@realDonaldTrump/posts/114776149269773065" rel="noreferrer noopener">asserted</a>, &#8220;Electric cars are fine, but not everyone should be forced to own one,&#8221; and claimed Musk &#8220;may get more subsidy than any human being in history,&#8220; casting doubt on the long-term viability of EV growth without government support.
Meanwhile, Tesla&#8217;s Chinese peer NIO, headquartered in Shanghai, continues to ramp up its operations and diversify its product lineup to meet evolving consumer demand.
The three-month total through June reached 72,056 vehicles in the second quarter, representing a year-over-year (YoY) growth of 25.6%.
As of the end of the month, NIO&#8217;s total cumulative deliveries stood at 785,714 vehicles.
The June numbers include shipments from three distinct brands under the company&#8217;s umbrella. The flagship NIO line contributed 14,593 vehicles, while 6,400 units were delivered under the more family-centric ONVO label.
Another 3,932 units came from the company&#8217;s premium compact EV brand, FIREFLY. This diverse approach appears to be a strategic bet on catering to varying market segments and household needs.
Bolstering its brand reputation, NIO said it received top rankings in the 2025 J.D. Power studies.
The ET5 and ET5T were named leading models in the mid-size battery electric sedan category, while the EC6 earned the highest score in the premium BEV segment of the NEV-APEAL study.
This marks the seventh consecutive year NIO has topped J.D. Power&#8217;s quality rankings in its category, a testament to consistent product performance and customer approval.
The company&#8217;s latest delivery results come as a positive signal for shareholders and EV market watchers.
Steady year-over-year growth indicates NIO&#8217;s execution strength amid intensifying competition from rivals like XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) and Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>).
In a separate release, Xpeng recorded a 224% YoY increase in June deliveries as the Tesla rival delivered 197,189 units in the first half of 2025, exceeding the total units delivered <a href="https://www.benzinga.com/markets/tech/25/07/46189960/tesla-rival-xpeng-records-224-surge-in-june-deliveries-crosses-2024-sales-mark-in-6-months" target="_blank" rel="noreferrer noopener">in the entire year in 2024</a>.
Li also released its latest delivery numbers on Tuesday, reporting 36,279 vehicles delivered in June 2025. This figure represents a <a href="https://www.benzinga.com/markets/tech/25/07/46190208/li-autos-strong-q2-deliveries-mask-junes-steep-decline" target="_blank" rel="noreferrer noopener">24.1% year-over-year decrease</a>.
Price Action: NIO shares are trading higher by 0.87% to $3.460 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46121729/nio-plots-hong-kong-entry-with-new-game-plan-to-challenge-tesla" target="_blank" rel="noreferrer noopener">NIO Plots Hong Kong Entry With New Game Plan To Challenge Tesla</a></li>
</ul>
Photo via Shutterstock

Asia

Equities

Markets

Movers

Tech

General

TSLA

XPEV

NIO's June Sales Surge As Trump Casts Doubt On EV Future

As of July 1, 2025, two stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Caseys General Stores Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>)</h3>
<ul class="wp-block-list">
<li>On June 9, Caseys General Stores reported better-than-expected fourth-quarter financial results and increased its quarterly dividend. "Inside same-store sales outperformed the industry, up 2.6%, or 7.1% on a two-year stack basis, led by strong performance in hot sandwiches and bakery as well as alcoholic and non-alcoholic beverages. Our fuel team grew market share and produced a healthy margin, as fuel gross profit increased 10.7% from the prior year," said Darren Rebelez, president and CEO of Casey's General Stores. The company's stock jumped around 16% over the past month and has a 52-week high of $514.32.</li>
<li>RSI Value: 70.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>CASY Price Action: Shares of Caseys gained 0.8% to close at $510.27 on Monday.</li>
<li>Edge Stock Ratings: 85.83 Momentum score with Value at 53.13. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/casy"><img loading="lazy" decoding="async" width="406" height="173" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01064654/image-1-2.png" alt="" class="wp-image-968414" style="width:312px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01064654/image-1-2.png 406w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/01064654/image-1-2-300x128.png 300w" sizes="(max-width: 406px) 100vw, 406px" /></a></figure>
<h3 class="wp-block-heading">Estee Lauder Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>)</h3>
<ul class="wp-block-list">
<li>On June 13, B of A Securities upgraded the stock from Underperform to Neutral and raised its price target from $68 to $94. The company's stock gained around 21% over the past month and <a href="https://www.benzinga.com/quote/EL">has a 52-week high</a> of $108.37.</li>
<li>RSI Value: 74.4</li>
<li>EL Price Action: Shares of Estee Lauder gained 0.9% to close at $80.80 on Monday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46169288/5-stocks-in-the-spotlight-wall-streets-most-accurate-analysts-weigh-in">5 Stocks In The Spotlight: Wall Street&#8217;s Most Accurate Analysts Weigh In</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Trading Ideas

CASY

Top 2 Risk Off Stocks You May Want To Dump This Quarter

Barclays analyst Saket Kalia initiates coverage on Omada Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMDA#NASDAQ">OMDA</a>) with a Overweight rating and announces Price Target of $21.

Price Target

Initiation

Analyst Ratings

OMDA

Barclays Initiates Coverage On Omada Health with Overweight Rating, Announces Price Target of $21

UniFirst Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) recently disclosed a new $100 million share repurchase authorization. The company is also set to release third-quarter earnings results before the <a href="https://www.benzinga.com/quote/UNF/earnings">opening bell on Wednesday, July 2.</a>
Analysts expect the Wilmington, Massachusetts-based company to report quarterly earnings at $2.09 per share, down from $2.20 per share in the year-ago period. UniFirst projects to report quarterly revenue of $614.5 million, compared to $603.33 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
With the recent buzz around UniFirst, some investors may be eyeing potential gains from the company's dividends. As of now, UniFirst offers an annual dividend yield of 0.74%. That&#8217;s a quarterly dividend amount of 35 cents per share ($1.40 a year).
To figure out how to earn $500 monthly from UniFirst, start with a yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by UniFirst's $1.40 dividend: $6,000 / $1.40 = 4,286 shares.
So, an investor would need to own approximately $806,711 worth of UniFirst, or 4,286 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.40 = 857 shares, or $161,305 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, since the stock price fluctuates over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
UNF Price Action: Shares of UniFirst gained by 1% to close at $188.22 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46169288/5-stocks-in-the-spotlight-wall-streets-most-accurate-analysts-weigh-in">5 Stocks In The Spotlight: Wall Street&#8217;s Most Accurate Analysts Weigh In</a></li>
</ul>
Image: Shutterstock

Earnings

Long Ideas

How To Earn $500 A Month From UniFirst Stock Ahead Of Q3 Earnings

U.S. stocks settled higher on Monday, with the S&amp;P 500 hitting another record close.
The Dow Jones closed higher by around 275 points to 44,094.77 on Monday. The S&amp;P 500 rose 0.52% to 6,204.95, while the Nasdaq Composite climbed 0.47% to 20,369.73 during Monday's session.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Yi Fu Lee
<ul class="wp-block-list">
<li>Analyst Firm: Cantor Fitzgerald</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Reiterated an Overweight rating on Domo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>) with a price target of $17 on June 25. This analyst sees around 22% upside in the stock.</li>
<li>Recent News: On June 26, Domo announced an expanded collaboration with Snowflake to deliver a comprehensive suite of applications on Snowflake Marketplace.</li>
</ul>
Analyst: Leo Mariani
<ul class="wp-block-list">
<li>Analyst Firm: Roth Capital</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Initiated coverage on EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Buy rating and a price target of $69 on June 24. This analyst sees around 18% upside in the stock.</li>
<li>Recent News: On April 22, EQT posted upbeat quarterly earnings.</li>
</ul>
Analyst: Josh Sullivan
<ul class="wp-block-list">
<li>Analyst Firm: Benchmark</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Maintained a Buy rating on Kratos Defense &amp; Security Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) and boosted the price target from $40 to $48 on June 23. This analyst sees around 3% upside in the stock.</li>
<li>Recent News: On June 30, Kratos Defense &amp; Security Solutions announced the completion of public offering of $575 million of common stock at $38.50 per share.</li>
</ul>
Analyst: Patrick Molley
<ul class="wp-block-list">
<li>Analyst Firm: Piper Sandler</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Assumed an Overweight rating on Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) with a price target of $75 on June 24. This analyst sees around 17% upside in the stock.</li>
<li>Recent News: On May 6, Upstart Holdings issued second-quarter sales guidance below estimates.</li>
</ul>
Analyst: Jay McCanless
<ul class="wp-block-list">
<li>Analyst Firm: Wedbush</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Reiterated an Outperform rating on The GEO Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) with a price target of $36 on June 23. This analyst sees around 50% upside in the stock.</li>
<li>Recent News: On July 1, GEO Group entered into purchase agreement with SDCC Middle Block to acquire 770-bed Western Region Detention facility in San Diego, California for $60 million.</li>
</ul>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46190223/top-3-tech-stocks-that-could-lead-to-your-biggest-gains-in-july">Top 3 Tech Stocks That Could Lead To Your Biggest Gains In July</a> </li>
</ul>
Photo via Shutterstock

DOMO

KTOS

UPST

5 Stock Picks For June From Wall Street's Most Accurate Analysts

Barclays analyst Gena Wang upgrades Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) from Equal-Weight to Overweight and raises the price target from $51 to $57.

Upgrades

IONS

Barclays Upgrades Ionis Pharmaceuticals to Overweight, Raises Price Target to $57

<ul>
<li>ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene, making it the broadest label for this medicine in the world.</li>
<li>In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride, demonstrating greater improvement in CFTR function.</li>
<li>Approximately 31,000 people with CF in the EU are now eligible for this new highly effective modulator therapy.</li>
</ul>

Biotech

Large Cap

Health Care

VRTX

The European Commission Approves Vertex Pharmaceuticals' Alyftrek (Deutivacaftor/Tezacaftor/Vanzacaftor) For Cystic Fibrosis Patients Ages 6 Years And Older Who Have At Least One Non-class I Mutation In The Cystic Fibrosis Transmembrane Conductance Regulator Gene

JP Morgan analyst Hong Zhang maintains Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) with a Overweight and lowers the price target from $32 to $30.

JP Morgan Maintains Overweight on Weyerhaeuser, Lowers Price Target to $30

Cryptocurrency markets are trading slightly down on Tuesday as spot ETF inflows ease after a 15-day streak and Bitcoin continues to consolidate below the $107,000 level, reflecting short-term indecision despite broader bullish sentiment.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$106,425.08</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,455.16</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$149.03</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.19</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1610</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001126</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction volume increased by 90.4% and 114.4%, respectively. Daily active addresses for BTC rose 32.1% while ETH saw a 9.1% drop.</li>
<li>Coinglass data shows 84,056 traders were liquidated in the past 24 hours for $199.23 million.</li>
<li>SoSoValue data shows net inflows of $102.1 million into spot Bitcoin ETFs on Monday, while spot Ethereum ETFs saw net outflows of $31.8 million.</li>
</ul>
Trader Notes: Crypto trader Degen Hardy <a href="https://x.com/Degen_Hardy/status/1939977061516693701">remains</a> on the sidelines, reiterating he has entered no long positions yet. 
He's watching three key price levels: $100,900 – Untapped weekly/daily support, $96,800 – Point of Control (PoC) for the macro range and $91,000–$92,000 – The CME gap zone. 
These zones aren't predictions but potential entry points should price revisit them.
BitBull sees Bitcoin preparing for its final push upward.
With the weekly RSI still below overbought, he believes there&#8217;s still room for upside without immediate exhaustion. His forecast: Bitcoin over $160,000 in 2025, with a likely peak in Q4.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> seems to be preparing for its final leg up. Weekly RSI is still below the overbought zone, so there&#39;s nothing to be panicked about. I think BTC is going above $160K+ in 2025 and will peak in Q4 2024. <a href="https://t.co/KIM3pqL4sm">pic.twitter.com/KIM3pqL4sm</a>
&mdash; BitBull (@AkaBull_) <a href="https://twitter.com/AkaBull_/status/1939981826870980697?ref_src=twsrc%5Etfw">July 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Michael van de Poppe <a href="https://x.com/CryptoMichNL/status/1939990866283626790">notes</a> Ethereum tightly consolidating, suggesting a breakout may be imminent. He sees growing momentum that could soon translate into a significant move.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a> consolidates before the next big breakout is on the horizon. <a href="https://t.co/EClcJBp1sX">pic.twitter.com/EClcJBp1sX</a>
&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1939990866283626790?ref_src=twsrc%5Etfw">July 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Galaxy <a href="https://x.com/galaxyBTC/status/1939915571664953718">likens</a> XRP's current setup to late 2017, pointing to a similarly structured RSI and price action that hints at explosive potential. Sentiment is building as the token continues to hold strength near key levels.
Trader Tardigrade <a href="https://x.com/TATrader_Alan/status/1939972761545580798">flagged</a> an Inverse Head &amp; Shoulders breakout on Dogecoin's 4-hour chart, with a successful retest of the neckline. The structure points toward bullish continuation.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46172312/bitcoins-perfect-storm-could-extend-bull-run-into-2026-report">Bitcoin&#8217;s &#8216;Perfect Storm&#8217; Could Extend Bull Run Into 2026: Report</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Continue Sideways On Muted Q3 Start

<ul>
<li>Acquisition enhances Honeywell's leading fire life safety portfolio in its Building Automation business, supports high growth energy storage and data center sectors</li>
<li>Li-ion Tamer's differentiated technology provides early detection of thermal runaway to help prevent devastating lithium-ion battery fires&nbsp;</li>
<li>With more than 30 global patents across its product lines, Li-ion Tamer is trusted by battery OEMs around the world&nbsp;</li>
</ul>
CHARLOTTE, N.C., July 1, 2025 /PRNewswire/ --&nbsp;Honeywell&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) today announced that it has acquired from Nexceris its Li-ion Tamer business, a leading off-gas detection solution for lithium-ion (li-ion) batteries that detects thermal runaway events. The acquisition enhances Honeywell's portfolio of best-in-class fire life safety technologies within its Building Automation segment and emerged from a partnership with Nexceris over the past 5 years to strategically address lithium-ion battery system safety.&nbsp;The transaction is expected to be immediately accretive to Honeywell's financials.

Honeywell Acquires Li-ion Tamer Business From Nexceris For Undisclosed Terms; Deal Expected To Be Immediately Accretive To Honeywell's Financials

Needham analyst Joshua Reilly initiates coverage on Crexendo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) with a Buy rating and announces Price Target of $8.

CXDO

Needham Initiates Coverage On Crexendo with Buy Rating, Announces Price Target of $8

Keybanc analyst Alex Markgraff maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Overweight and raises the price target from $60 to $110.

HOOD

Keybanc Maintains Overweight on Robinhood Markets, Raises Price Target to $110

Needham analyst Ryan MacDonald initiates coverage on Omada Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMDA#NASDAQ">OMDA</a>) with a Buy rating and announces Price Target of $23.

Needham Initiates Coverage On Omada Health with Buy Rating, Announces Price Target of $23

WIIM

AVAV

AeroVironment shares are trading lower after the company announced a proposed $750 million common stock offering and $600 million in convertible senior notes due 2030 to repay debt and expand manufacturing.

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

WYNN

Shares of casino stocks are trading lower after Macau June casino revenue reportedly rose.

JP Morgan analyst Joseph Greff upgrades Melco Resorts and Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLCO#NASDAQ">MLCO</a>) from Neutral to Overweight and raises the price target from $7.2 to $9.5.

JP Morgan Upgrades Melco Resorts and Enter to Overweight, Raises Price Target to $9.5

HC Wainwright &amp; Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>) with a Buy and lowers the price target from $7 to $5.

LEXX

HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $5

Tesla shares are trading lower amid disagreements between CEO Elon Musk and President Donald Trump. Additionally, Tesla registrations in Sweden and Denmark reportedly fell during June.

Needham analyst Charles Shi maintains Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) with a Buy and raises the price target from $225 to $270.

Needham Maintains Buy on Taiwan Semiconductor, Raises Price Target to $270

Press Releases

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Comments

Autolus Therapeutics

Autolus Therapeutics (AUTL) オプション

Autolus Therapeutics (NASDAQ:AUTL) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル